CClinicalTrials.gg
CompletedNCT03292575AODUpdated Jun 4, 2019

Study of the Follow-up of Stroke Treated With Anticoagulants

An observational study in Stroke, sponsored by Centre Hospitalier Universitaire Dijon. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2019-06-04.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
441
Sex
All
01

Study summary

Stroke is a major public health problem as it is very frequent (140,000 cases/year in France), and very serious (leading cause of death, 2nd leading cause of dementia, 3rd leading cause of handicap). Ischemic cardio-embolic stroke accounts for around 25% of ischemic strokes, and ischemic cardio-embolic stroke in a context of cardiac arrhythmia due to atrial fibrillation (CAAF) is the leading non-atheromatous cause. The aim of this study is to optimise the secondary prevention of CAAF-related stroke identified at the University Hospital of Dijon Burgundy in the framework of the recommendations of the '2010-2014 stroke plan' and the Compulsory Consultation at the 6th month (Directive DGOS//2015/262 of the 3rd August 2015)

02

Conditions studied

  • Stroke

Browse trials for

03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patient with stroke resulting from occlusion of a cerebral artery (cerebral infarction) with a clot detached from the heart that exhibits an arrhythmia by Auricular Fibrillation or the occurrence of intracerebral hemorrhage

Inclusion criteria

  • patients managed for stroke at the stroke unit of Dijon University Hospital for CAAF-related cardio-embolic stroke

Exclusion criteria

Exclusion Criteria:

  • NA
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
441 participants (actual)
Patient registry
No

Groups and cohorts

  • Stroke related to CAAF

    Drug: Anticoagulants

Interventions

  • DrugAnticoagulants
05

What researchers measure

Primary outcomes

  1. rate of stroke recurrences

    Time frame: 12 months after inclusion

06

Study locations

1 site
  • CHU Dijon Bourgogne
    Dijon, 21079, France
07

Registry details

Key details

Study ID
NCT03292575
Lead sponsor
Centre Hospitalier Universitaire Dijon
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Jan 2016
Primary completion
Dec 2018
Completion
Dec 2018
Last update
Jun 4, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion